- Home
- FT vs DSGN Comparison
FT vs DSGN Comparison
Compare FT & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- DSGN
- Stock Information
- Founded
- FT 1988
- DSGN 2017
- Country
- FT United States
- DSGN United States
- Employees
- FT N/A
- DSGN N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- FT Finance
- DSGN Health Care
- Exchange
- FT Nasdaq
- DSGN Nasdaq
- Market Cap
- FT 187.3M
- DSGN 208.9M
- IPO Year
- FT N/A
- DSGN 2021
- Fundamental
- Price
- FT $7.52
- DSGN $3.95
- Analyst Decision
- FT
- DSGN Hold
- Analyst Count
- FT 0
- DSGN 1
- Target Price
- FT N/A
- DSGN $4.00
- AVG Volume (30 Days)
- FT 63.0K
- DSGN 85.4K
- Earning Date
- FT 01-01-0001
- DSGN 08-04-2025
- Dividend Yield
- FT 7.85%
- DSGN N/A
- EPS Growth
- FT N/A
- DSGN N/A
- EPS
- FT N/A
- DSGN N/A
- Revenue
- FT N/A
- DSGN N/A
- Revenue This Year
- FT N/A
- DSGN N/A
- Revenue Next Year
- FT N/A
- DSGN N/A
- P/E Ratio
- FT N/A
- DSGN N/A
- Revenue Growth
- FT N/A
- DSGN N/A
- 52 Week Low
- FT $5.97
- DSGN $2.60
- 52 Week High
- FT $7.23
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- FT 55.36
- DSGN 52.87
- Support Level
- FT $7.43
- DSGN $3.65
- Resistance Level
- FT $7.55
- DSGN $4.21
- Average True Range (ATR)
- FT 0.05
- DSGN 0.24
- MACD
- FT -0.00
- DSGN 0.00
- Stochastic Oscillator
- FT 75.00
- DSGN 41.50
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.